These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20359847)

  • 1. Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate.
    D'Eufemia P; Finocchiaro R; Celli M; Raccio I; Zambrano A; Tetti M; Smacchia P; Iacobini M
    Biomed Pharmacother; 2010 Apr; 64(4):271-4. PubMed ID: 20359847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
    D'Eufemia P; Finocchiaro R; Zambrano A; Tetti M; Ferrucci V; Celli M
    Biomed Pharmacother; 2007 May; 61(4):235-40. PubMed ID: 17275249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
    Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F
    Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.
    Otrock ZK; Azar ST; Shamseddeen WA; Habr D; Inati A; Koussa S; Mahfouz RA; Taher AT
    Ann Hematol; 2006 Sep; 85(9):605-9. PubMed ID: 16830143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study.
    Forni GL; Perrotta S; Giusti A; Quarta G; Pitrolo L; Cappellini MD; D'Ascola DG; Borgna Pignatti C; Rigano P; Filosa A; Iolascon G; Nobili B; Baldini M; Rosa A; Pinto V; Palummeri E
    Br J Haematol; 2012 Jul; 158(2):274-282. PubMed ID: 22571408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intramuscular neridronate in postmenopausal women with low bone mineral density.
    Adami S; Gatti D; Bertoldo F; Sartori L; Di Munno O; Filipponi P; Marcocci C; Frediani B; Palummeri E; Fiore CE; Costi D; Rossini M
    Calcif Tissue Int; 2008 Nov; 83(5):301-7. PubMed ID: 18946626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous neridronate in adults with osteogenesis imperfecta.
    Adami S; Gatti D; Colapietro F; Fracassi E; Braga V; Rossini M; Tatò L
    J Bone Miner Res; 2003 Jan; 18(1):126-30. PubMed ID: 12510813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
    Morabito N; Gaudio A; Lasco A; Catalano A; Atteritano M; Trifiletti A; Anastasi G; Melloni D; Frisina N
    J Bone Miner Res; 2004 Nov; 19(11):1766-70. PubMed ID: 15476575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
    Gatti D; Antoniazzi F; Prizzi R; Braga V; Rossini M; Tatò L; Viapiana O; Adami S
    J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.
    Voskaridou E; Christoulas D; Antoniadou L; Terpos E
    Acta Haematol; 2008; 119(1):40-4. PubMed ID: 18253025
    [No Abstract]   [Full Text] [Related]  

  • 13. [Modifications of markers of bone resorption in patients affected by glucocorticoid induced osteoporosis (GIOP) treated with neridronate].
    Benucci M; Dolenti S; Saviola G; Manfredi M
    Recenti Prog Med; 2006 Jan; 97(1):24-7. PubMed ID: 16535926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial.
    Voskaridou E; Christoulas D; Konstantinidou M; Tsiftsakis E; Alexakos P; Terpos E
    Haematologica; 2008 Oct; 93(10):1588-90. PubMed ID: 18698086
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral bisphosphonates improve Bone Mineral Density in adults with cystic fibrosis.
    Cawood TJ; McKenna MJ; Gallagher CG; Smith D; Wen YC; Gibney J; Dodd JD; O'Shea D
    Ir Med J; 2005 Oct; 98(9):270-3. PubMed ID: 16300106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate treatment of pediatric bone disease.
    Speiser PW; Clarson CL; Eugster EA; Kemp SF; Radovick S; Rogol AD; Wilson TA;
    Pediatr Endocrinol Rev; 2005 Dec; 3(2):87-96. PubMed ID: 16361982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
    Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
    Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
    Cruse LM; Valeriano J; Vasey FB; Carter JD
    J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone turnover 18 months after a single intravenous dose of zoledronic acid.
    Borba VZ; Paz-Filho G; Kulak CA; Seibel MJ; Bilezikian JP
    Int J Clin Pract; 2007 Jun; 61(6):1058-62. PubMed ID: 17504370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
    Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
    Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.